We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

85 hedge funds and large institutions have $393M invested in Krystal Biotech in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 20

12% more funds holding

Funds holding: 76 → 85 (+9)

6.99% more ownership

Funds ownership: 58.01% → 65% (+7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $397M → $393M (-$4.87M)

Holders
85
Holders Change
+9
Holders Change %
+11.84%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
36
Reduced
20
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$13.8M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$9.95M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$9.73M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$8.9M
5
BlackRock
BlackRock
New York
+$6.71M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$6.71M
2
Millennium Management
Millennium Management
New York
-$4.74M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.09M
4
O
OrbiMed
New York
-$1.79M
5
MIM
Monashee Investment Management
Massachusetts
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
76
STRS Ohio
Ohio
$79K – – –
Victory Capital Management
77
Victory Capital Management
Texas
$60K +$77.7K +1,739 New
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$45.8K +$56.5K +1,263 +2,296%
Bank of Montreal
79
Bank of Montreal
Ontario, Canada
$32K +$8.45K +189 +26%
AIP
80
Ameritas Investment Partners
Nebraska
$27K – – –
TRCT
81
Tower Research Capital (TRC)
New York
$23K -$49.7K -1,112 -62%
Canada Life
82
Canada Life
Manitoba, Canada
$21K -$54.1K -1,210 -66%
DWA
83
Dorsey Wright & Associates
California
$16K – – –
MAM
84
Meeder Asset Management
Ohio
$8K +$11K +247 New
GGHC
85
Gilder Gagnon Howe & Co
New York
$1K +$983 +22 New
Point72 Asset Management
86
Point72 Asset Management
Connecticut
– -$4.09M -101,700 Closed
MIM
87
Monashee Investment Management
Massachusetts
– -$1.41M -35,000 Closed
MF
88
Magnetar Financial
Illinois
– -$483K -12,000 Closed
BFM
89
Boothbay Fund Management
New York
– -$350K -8,685 Closed
Goldman Sachs
90
Goldman Sachs
New York
– -$330K -8,184 Closed
1 2 3
4

KRYS Hedge Fund Activity: Q3 2019 in Review

85 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2019, worth a combined $393M — down 1.2% from $397M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new KRYS positions and 5 closed out — a net gain of 9 holders — while 36 added to existing stakes and 20 trimmed.

The largest buyer was State Street, adding an estimated $13.8M. The largest seller was Artal Group, cutting an estimated $6.71M.

  • 85 institutional investors held Krystal Biotech (KRYS) as of Q3 2019, up from 76 in Q2 2019.
  • Funds reported $393M of Krystal Biotech stock for Q3 2019, down 1.2% quarter-over-quarter.
  • 14 funds opened new Krystal Biotech positions in Q3 2019 and 5 closed out, a net change of +9 holders.
  • The largest Krystal Biotech buyer in Q3 2019 was State Street, an estimated $13.8M added.
  • The largest Krystal Biotech seller in Q3 2019 was Artal Group, an estimated $6.71M sold.

Based on aggregated 13F filings for Q3 2019.